相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma
Jean-Yves Blay et al.
CLINICAL CANCER RESEARCH (2008)
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer
Gabriella Ferrandina et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens
C. N. Krasner et al.
BRITISH JOURNAL OF CANCER (2007)
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
David G. Mutch et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Trabectedin- A review of its use in the management of soft tissue sarcoma and ovarian cancer
Natalie J. Carter et al.
DRUGS (2007)
Ovarian cancer
Nicoletta Colombo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2006)
Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients-long-term results of a Phase II study
M Baur et al.
CANCER INVESTIGATION (2006)
Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails
C Sessa et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Transient reversal of HIV-associated motor neuron disease following the introduction of highly active antiretroviral therapy
L Calza et al.
JOURNAL OF CHEMOTHERAPY (2004)
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
AN Gordon et al.
GYNECOLOGIC ONCOLOGY (2004)
Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study
ML Rothenberg et al.
GYNECOLOGIC ONCOLOGY (2004)
Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma
WT Huinink et al.
ANNALS OF ONCOLOGY (2004)
Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum
P Rosenberg et al.
ACTA ONCOLOGICA (2002)
Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens
MG Cantu et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: A Japanese Cooperative Study
N Katsumata et al.
ANNALS OF ONCOLOGY (2000)
分享论文
